Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer or Normal Volunteers
Sponsor study identifier
Secondary identifiers
observational
86
1 country
1
Study Start
August 9, 2000
Actual (reported)Primary Completion
June 28, 2024
Actual (reported)Study Completion
June 28, 2024
Actual (reported)This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings may provide information needed to develop methods of combating drug resistance. Patients with cancer who are 18 years or older may be eligible for this study. Participants will have 40 milliliters (3 tablespoons) of blood drawn at the beginning of the study; additional samples will be obtained periodically during the course of treatment. A small sample of tumor or normal tissue will be taken from patients who undergo surgery or tumor biopsy (removal of a small piece of tumor) for medical reasons or as part of a research treatment protocol. Patients who do not require surgery or biopsy may be asked permission to obtain a tumor sample. Depending on the location of the tumor, this may be done by: 1) withdrawing bone marrow through a small needle; 2) removing fluid from the chest or abdomen; 3) removing a small tumor sample through a needle; or 4) removing the sample with a small incision into or around the tumor. These procedures will be done only if they are of low risk to the patient.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 28, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 9, 2000
Actual (reported)November 14, 2001
Actual (reported)November 15, 2001
Actual (reported)June 28, 2024
Actual (reported)June 28, 2024
Actual (reported)To obtain specimens to develop assays
Obtain sufficient number of samples for a given test.
End of study
Cancer patients providing tissue for research studies
normal volunteers providing samples for research studies
Patients with malignancy requiring a surgical procedure or biopsy for any medical indication. Healthy volunteers not requiring biopsy for a medical indication.
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
William D Figg, Pharm.D.
National Cancer Institute (NCI)
86 participants (actual enrollment reported by the registry).
First Submitted
November 14, 2001
First Posted
November 15, 2001
Study Start
August 9, 2000
Actual (reported)Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
Contact the study team to confirm eligibility.
Primary Completion
June 28, 2024
Actual (reported)Study Completion
June 28, 2024
Actual (reported)Last Updated
July 1, 2024
Record last verified: 2024-06
.All IPD recorded in the medical record will be shared with intramural investigators upon request.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: